AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00865657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XANAX XR® 3 mg tablets, single dose
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
Study NCT03013192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: Patients will receive automated text message reminders regarding their physical therapy
Study NCT01066871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 10 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
Study NCT01066871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 30 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
Study NCT01066871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 100 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
Study NCT01066871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
Study NCT01084538 — intervention group
Intervention type: DRUG
Intervention: Zemplar iv (paricalcitol iv)
Description: Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
Study NCT00774072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin (Gernebcin®)
Description: 1 ml / day in each nostril
Study NCT00774072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin (Gernebcin®)
Description: 1 ml / day in each nostril
Study NCT02523404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT02523404 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT04760535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)
Description: Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
Study NCT04760535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth-borne Hyrax-type maxillary expander
Description: The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
Study NCT01570842 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurements
Description: All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
Study NCT01570842 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue samples
Description: Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
Study NCT03574038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
Study NCT03574038 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
Study NCT02041780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shearwave electrography
Study NCT02427243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Study NCT01689363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
Study NCT01689363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
Study NCT01689363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
Study NCT01845805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Study NCT01845805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study NCT03080818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic - Lactobacillus Rhamnosus GG
Description: 2 capsules per day for 90 days
Study NCT03080818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules per day for 90 days
Study NCT00612352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol High Dose, Ethanol Low Dose, and Placebo
Description: Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
Study NCT02244138 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adolescent CDSS
Description: computer decision support system (CDSS) for health care providers of adolescents in primary care
Study NCT00167154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone and placebo comparator
Description: Up to 2 mg risperidone or matching placebo daily
Study NCT00167154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and placebo comparator
Description: Up to 2 mg risperidone or matching placebo daily
Study NCT04080713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 9 mg prolonged release tablet
Study NCT00760513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMACOR
Description: 4 grammes daily, oral capsule
Study NCT00760513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 4 grammes daily, oral capsule (olive oil)
Study NCT01589926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure device
Description: BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Study NCT01589926 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Study NCT02607202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT02607202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02607202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00566813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Islet Cell Transplant
Description: 1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
Study NCT00566813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Islet Cell Transplant plus
Description: 1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: 1 dose of Trivalent Influenza Vaccine
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A
Description: 1 dose of Trivalent Influenza Vaccine with high A content
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + ¼ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + ¼ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + ½ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + ½ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine intradermal dose
Description: 1 dose of Trivalent Influenza Vaccine intradermal dose
Study NCT00848848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A intradermal dose
Description: 1 intradermal dose of Trivalent Influenza Vaccine + high A
Study NCT04661943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
Study NCT03544645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual material video
Description: an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
Study NCT03544645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed material brochure
Description: an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
Study NCT03923686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided drainage using LAMS with DPS
Description: Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
Study NCT03923686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided drainage using LAMS alone
Description: Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
Study NCT01788475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (dexamethasone) 0.7mg steroid implant
Study NCT01788475 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (dexamethasone) 0.7mg steroid implant
Study NCT03637413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hindmilk
Description: Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
Study NCT01450293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: 1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
Study NCT01450293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCH63 ME-TRAP, MVA ME-TRAP
Description: 5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
Study NCT01043094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 4mg
Description: Pitavastatin 4mg single dose
Study NCT01043094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4mg
Description: Pitavastatin 4mg single dose
Study NCT04136262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Description: Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
Study NCT04136262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study NCT04136262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study NCT04136262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Tripterygium wilfordii Hook F (TwHF)
Description: Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
Study NCT00691652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
Study NCT00691652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
Study NCT00691652 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
Study NCT00691652 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Total RNA will be processed for determination of gene expression by microarray
Study NCT00691652 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
Study NCT00691652 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00691652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
Study NCT00691652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
Study NCT00765947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 or 300 mg
Study NCT00765947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 or 25 mg
Study NCT00765947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 or 10 mg
Study NCT00850122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin
Description: Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8
Study NCT01270321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
Study NCT01270321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
Study NCT01270321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and Pasireotide
Description: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
Study NCT01875263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloxacilin
Description: 2g/4 hours i.v., 5 days
Study NCT01875263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cloxacillin
Description: 2g/4h 14 days Standard therapy
Study NCT01875263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 500 mg v.o./24h, 9 days
Study NCT03947008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intuitive Eating Program
Description: A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions.
Study NCT01605682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
Study NCT01605682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fresh berry extract.
Description: Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
Study NCT01872481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.